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A comparison of standard and high-dose 
regimens for the initiation of amiodarone 
therapy 
The effects of two regimens for the initiation of amiodarone therapy were compared in 92 
patients with inducible sustained ventricular tachycardia (VT) at baseline electrophysiologic 
testing. Two groups of 46 patients each received a total of 16.6 gm of oral amiodarone before 
follow-up electrophysiologic testing. Group A (standard dose) received 1200 mglday for 14 days, 
and group B (high dose) received 2400 mglday for 7 days. Amiodarone suppressed the induction 
of sustained VT in six subjects (13%) in group A versus 10 (22%) in group B (p = NS). In 
subjects who continued to have inducible VT after amiodarone loading, the mean increase in 
cycle length of induced VT was similar in group A (A = 65 + 73 msec) and group B (A = 76 + 59 
msec). The mean increase in sinus cycle length, AH and HV intervals, paced QRS duration, and 
ventricular refractory periods was also not significantly different between the two groups. Side 
effects developed in 10 (22%) patients in group B but were serious only in one, and one patient 
required a reduction in dosage. Thus compared to the 1Cday standard-dose regimen, the 7-day 
high-dose regimen was well tolerated and had similar effects on VT inducibility and 
electrophysiologic variables. Its use may significantly shorten the duration of hospitalization in 
patients with life-threatening inducible VT who are undergoing loading with amiodarone on an 
inpatient basis. (AM HEART J 1992;124:366.) 
Joni Summitt, MD, Fred Morady, MD, and Alan Kadish, MD Ann Arbor, Mich. 
Amiodarone is a widely used agent for the treatment 
of life-threatening ventricular arrhythmias. Results 
of several studies have shown electrophysiologic 
testing to be useful in predicting clinical responses in 
patients treated with amiodarone.1-7 Amiodarone 
possesses unusual pharmacokinetic properties, and a 
prolonged period of time is required to achieve its 
steady-state electrophysiologic effects.sg In an at- 
tempt to overcome a long delay in the onset of an an- 
tiarrhythmic effect, a period of high-dose loading has 
been recommended based on pharmacokinetic and 
clinical data.1°-12 A frequently administered regimen 
consists of 1200 mg given for 14 days before electro- 
pharmacologic testing. 3. 7,13 Because most patients 
receiving amiodarone have life-threatening arrhyth- 
mias, they are generally hospitalized during the 
loading phase. We hypothesized that the same total 
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dosage of drug given over a shorter period of time 
might have similar efficacy and therefore shorten the 
hospitalization phase for amiodarone loading. This 
prospective study was designed to compare the 
effects of a loading regimen consisting of 2400 mglday 
of amiodarone for 7 days with those of a more typical 
regimen consisting of 1200 mg/day for 14 days. 
METHODS 
Study patients. The patient population consisted of two 
groups of 46 patients each, who had spontaneous sustained 
ventricular tachycardia (VT) or ventricular fibrillation, 
symptomatic nonsustained VT or unexplained syncope in 
the setting of organic heart disease and inducible sustained 
monomorphic VT in the drug-free state. In addition, each 
patient had unsuccessful treatment with a class I antiar- 
rhythmic drug and was thought to be an appropriate can- 
didate for treatment with amiodarone. The clinical char- 
acteristics of the two groups are shown in Table I. 
Electrophysiologic study protocol. Electrophysiologic 
studies were performed in the fasting nonsedated state af- 
ter written informed consent was obtained. All subjects 
underwent a baseline study after antiarrhythmic drugs had 
been discontinued for at least five half-lives. Electrophys- 
iologic testing was also performed after one of two oral 
amiodarone loading regimens. Two or more quadripolar 
electrode catheters were inserted via a femoral vein and 
positioned in the high right atrium and His bundle position 
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Table I. Clinical characteristics 
Variables 
Group A (standard dose) Group B (high dose) 
Mean SD Range Mean SD Range 
Age (pr) 
Ejection fraction I (i ) 
64 9 42-81 
29 9 14-52 
No. 5 
66 9 45-84 
34 11 l&57 









Syncope t NSVT 
NSVI’ without syncope 
43 93 
3 7 
44 96 45 98 
2 4 1 b) 
29 63 32 70 
a 17 11 24 
9 20 3 6 
42 97 
4 9 
NSVT. Nonsu:;tained ventricular tachycardia; VTIVF, sustained ventricular tachycardia or ventricular fibrillation. 
and later repositioned in the right ventricular apex and 
right ventricular outflow tract. Blood pressure was contin- 
uously monitored via a femoral artery catheter. Intracar- 
diac electrograms and ECG leads were recorded with a 
Siemens-Elema Mingograf-7 recorder (Siemens Pacesetter 
Inc., Sylmar, Calif.). ECG leads Vi, I, and III were recorded 
during the stimulation protocol. For measurements of QRS 
and QT duration, the six standard limb leads were re- 
corded. A programmable stimulator (Bloom Associates 
Ltd., Reading, Pa.) was used to deliver pacing stimuli of 2 
msec duration at twice diastolic threshold. 
The stimulation protocol used for initiating VT con- 
sisted of scanning early diastole with one to three extra- 
stimuli during ventricular pacing at drive cycle lengths of 
600, 500, and 400 msec at the right ventricular apex and 
right ventricular outflow tract. Coupling intervals were 
limited to 200 msec in all but one patient to minimize the 
induction of nonclinical arrhythmias. In that patient a 
coupling interval of 180 msec reproducibly induced mono- 
morphic VT, which was similar to that patient’s spontane- 
ous morphology. End points of the study were completion 
of the stimulation protocol or the reproducible induction of 
sustained monomorphic VT. Criteria for a positive results 
baseline electrophysiologic tests included induction of sus- 
tained VT or hypotensive VT requiring termination before 
30 seconds. Criteria for an acceptable response to amio- 
darone at follow-up electrophysiologic testing were the 
elimination of inducible tachycardia or slowing of induced 
VT to a cycle length of greater than 350 msec associated 
with a mean blood pressure greater than or equal to 80 mm 
of Hg. Even if a well-tolerated VT was induced during 
electropharmacologic testing, the stimulation protocol was 
completed to determine whether other more rapid VT 
morphologies could also be induced. 
350 msec, and ventricular effective and functional refrac- 
tory periods (measured at the right ventricular apex) at 
drive cycle lengths of 600 and 400 msec. For the determi- 
nation of ventricular refractory periods, an eight-beat drive 
train and a 4-second intertrain pause were used. A condi- 
tioning period of 1 minute with drive trains and an inter- 
train pause was used before determination of refractoriness 
was begun. The SI-Ss coupling interval was decreased in 10 
msec steps until Si-Ss failed to capture on two consecutive 
drive trains at a given coupling interval. In three patients 
in each group, measurements were not performed at a cy- 
cle length of 600 msec because of sinus tachycardia. 
Amiodarone administration. After baseline electrophys- 
iologic testing, amiodarone was administered orally by 
means of one of two dosing regimens, both of which 
consisted of a total dose of 16.8 gm of amiodarone during 
the loading phase. Group A (standard dose) consisted of 46 
patients who received a dosage of 1200 mg/day for 14 days 
before repeating the electrophysiologic studies. These were 
46 consecutive patients who had been treated in our insti- 
tution who met the inclusion criteria. The next 46 patients 
were prospectively treated with high-dose amiodarone. 
They constituted group B (high dose), which consisted of 
the next 46 patients who met the inclusion crit,eria and re- 
ceived 2400 mglday of amiodarone for 7 days before 
repeating the electrophysiologic studies. In addition, 28 
sub.jects from group B who continued to have inducible 
hemodynamically unstable monomorphic VT after 1 week 
of high-dose loading were continued to take 2400 mglday 
of amiodarone for another 7 days and underwent repeat 
electrophysiologic testing. Plasma concentrations of amio- 
darone were determined at the time of serial electrophys- 
iologic studies. In group B side effects were recorded at the 
time of follow-up electrophysiologic tests. 
The electrophysiologic parameters assessed at each study Definitions. Sustained VT was defined as lasting more 
included sinus cycle length, AH, HV, and QT intervals than 30 seconds or requiring termination before 30 seconds 
during sinus rhythm and during atria1 pacing at a cycle because of hemodynamic compromise. Nonsustained VT 
length of 600 msec, QRS duration measured on the fif- was defined as tachycardia six complexes t.o 30 seconds in 
teenth beat of ventricular pacing at cycle lengths of 600 and duration. Monomorphic VT had a constant beat-to-beat 
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Group A Group B 
Fig. 1. Number of patients in group A and group B who had no inducible ventricular tachycardia (VT) 
(hatched bars), hemodynamically well-tolerated VT induced (shaded bars), or rapid VT induced (solid 
bars) during follow-up electrophysiologic study on amiodarone therapy. There were no significant differ- 
ences between groups. 
QRS morphology when viewed simultaneously in at least 
three leads. The ventricular effective refractory period was 
defined as the longest Si-Ss coupling interval that repro- 
ducibly failed to elicit a ventricular response. The ventric- 
ular functional refractory period was defined as the short- 
est Vi-V2 interval obtained during delivery of single ven- 
tricular extrastimuli. 
Data analysis. Intervals were measured at paper speeds 
of 100 to 250 mm/set. AH, HV, and QT intervals, cycle 
length of induced VT, and paced QRS duration were 
determined to the nearest 5 msec. All measurements were 
made by a single observer (J. S.). The cycle length of 
induced VT was determined 5 seconds after its initiation. 
The change in cycle length of induced VT at serial electro- 
physiologic studies was compared in two ways: change in 
cycle length of VTs with similar morphologies (if present) 
and change in cycle length of the fastest VT induced. Chi- 
square analysis was used to compare inducibility and 
change in cycle length of induced VT. Analysis of variance 
was used to compare electrophysiologic parameters be- 
tween groups A and B, as well as the changes from baseline 
to l- and Z-week studies in group B. In comparing changes 
within group B from the l-week to the 2-week study, only 
data from patients who underwent a Z-week study were 
used. Data are presented as mean s standard deviation. A 
p value of less than 0.05 was considered statistically signif- 
icant. 
RESULTS 
Effects on the induction of ventricular tachycardia. 
Amiodarone prevented the induction of sustained 
VT in 6 of 46 (13%) patients in group A versus 10 of 
46 (22%) in group B (p = NS; Fig. 1). The sustained 
monomorphic VT induced during electrophysiologic 
testing on a regimen of amiodarone therapy was he- 
modynamically well tolerated in six additional pa- 
tients in group A. The 12 patients with a favorable 
response to the drug were discharged on a regimen of 
chronic oral amiodarone therapy. The remaining 34 
patients in group A were treated with combination 
antiarrhythmic drug therapy or an implantable car- 
dioverter-defibrillator. Among the 36 patients in 
group B who continued to have inducible sustained 
monomorphic VT after 1 week of amiodarone ther- 
apy, 28 with poorly tolerated VT underwent an ad- 
ditional week of high-dose amiodarone loading fol- 
lowed by electrophysiologic study (see below), two 
underwent placement of an implantable cardiovert- 
er-defibrillator, five with hemodynamically tolerated 
inducible VT were discharged on a regimen of ami- 
odarone, and one with induced hemodynamically 
unstable VT underwent a repeat study at another 
institution. 
Effects on ventricular tachycardia cycle length. Ami- 
odarone increased the cycle length of the fastest VT 
induced from 271 IL 45 msec to 356 f 76 msec in 25 
patients in group A (A = 85 it_ 73 msec; p < 0.01) and 
from 264 f 52 msec to 342 -+ 68 msec in 20 patients 
in group B (A = 78 t 59 msec; p < 0.01). The in- 
crease in cycle length of induced VT was similar in 
the two groups. When considering only VT of the 
same morphology, amiodarone increased the cycle 
length of induced VT from 280 + 48 msec to 374 + 83 
msec in group A (A = 92 f 66 msec; p < 0.01) and 
from 270 -+ 56 msec to 356 * 92 msec (A = 85 +- 53 
msec; p < 0.01) in group B. Once again the changes 
in cycle length produced by both loading dose regi- 
mens were similar. The proportion of subjects who 
demonstrated an increase in tachycardia cycle length 
of at least 100 msec was also not significantly differ- 
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Paced 600 msec 
HV in1 erval 
SR 
Paced 600 msec 
QT interval 
SR 
Paced 600 msec 
QRS duration 
Paced 600 msec 
Paced 350 msec 
VERP 
600 msec DCL 
400 msec DCL 
VFRP 
600 msec DCL 
400 msec DCL 
Baseline 
786 k 158 
101 + 30 
121 k 49 
56 k 11 
55 + 12 
383 + 33 
367 t 32 
169 -+ 22 
168 f  21 
257 k 18 
237 I 16 
284*17 
261 -+ 16 
Group A 
2 weeks 
899 k 160 
127 t 28 
209 * 97 
61 t 11 
64 k 14 
456 zk 49 
432 f 40 
200 + 26 
218 + 34 
288 t 19 
267 t 18 
317 + 18 
292 * 19 
Change Baseline 
108 k 146* 829 + 103 
26 + 27* 96 f 28 
84 + 78* 118 f 41 
618 50 +- 8 
9 t lo* 50 f 7 
72 of: 38* 393 i- 34 
63 + 36* 375 XL 29 
31 + 18* 166 f 22 
49 + 26* 168 t 23 
31 + 20* 260 +- 20 
29 k 21* 242 + 20 
33 + 23* 283 + 19 
31 k 20* 265 + 18 
Group B 
I week 
941 + 128 
120 k 34 
201 -c 85 
57 t 9 
59 t 10 
480 + 55 
453 ?I 49 
199 rt: 26 
216 + 42 
295 * 20 
278 + 29 
322 + 22 
297 2k 20 
Change 
113 + 137* 
23 + 16* 
85 + 72* 
7 k 8* 
9 f 9* 
86 t 53* 
77 _t 46* 
33 x!z 22* 
48 + 33* 
34 t 30* 
36 k 35* 
39 k 26* 
32 k 22* 
DCL, Drive cycle length; SR, sinus rhythm; XL, sinus cycle length; VERP, ventricular effective refractory period; VFRP, ventricular functional refractory 
period. 
p = NS for all comparisons of change in group A versus group B. 
*p < 0.05 baseline versus follow-up study. 
ent between the two groups both with regard to the 
fastest tachycardia induced (45 % of group A vs 36 % 
of group B) and induced tachycardias of similar 
morphology (50 % of group A vs 35 % of group B). 
Effects on ventricular conduction and refractoriness 
(Table II). Amiodarone significantly increased the 
paced QRS duration and ventricular refractory peri- 
ods in both groups of patients. The effects of amio- 
darone on paced QRS duration were rate dependent 
and similar for the two dosing regimens. At a paced 
cycle length of 600 msec, QRS duration increased by 
31 2 18 msec in group A versus 33 + 22 msec in 
group B (p = NS). At a paced cycle length of 350 
msec, QRS duration increased by 49 + 26 msec in 
group A versus 48 f 33 msec in group B (p = NS). 
Likewise the increase in ventricular effective and 
functional refractory periods measured at drive cycle 
lengths of 600 and 400 msec were similar in the two 
groups. For example, at a drive cycle length of 600 
msec, the effective refractory period increased from 
257 + 18 msec to 288 k 19 msec (A = 31 f 20 msec; 
p < 0.01) in group A versus from 260 f 20 msec to 
295 -+ 20 msec (A = 34 f 30 msec; p < 0.01) in group 
B (p = NS for group A vs group B). 
Other electrophysiologic effects (Table II). Amio- 
darone significantly increased the sinus cycle length 
and AH, HV, and QT intervals in both groups of pa- 
tients. Once again the changes in the two groups were 
similar. After amiodarone therapy the sinus cycle 
length increased by 108 f 146 msec in group A ver- 
sus 113 +- 137 msec in group B. During sinus rhythm 
there was an increase in the AH interval of 26 f 27 
msec in group A versus 23 _+ 16 msec in group B, an 
increase in the HV interval of 6 + 8 msec in group A 
versus 7 f 8 msec in group B, and an increase in the 
QT interval of 72 f 38 msec in group A vs 85 & 53 
msec in group B. During atria1 pacing at a cycle length 
of 600 msec, there was no significant difference in ef- 
fect on these same parameters between the two 
groups. 
Amiodarone effects in group 6 (Table III). Among 
the 28 subjects in group B who received a second week 
of therapy with a dose of 2400 mglday because of an 
inadequate response to 1 week of therapy, two addi- 
tional subjects had suppression of inducible sus- 
tained VT at the 2-week study. Five additional 
patients had only hemodynamically well-tolerated 
VT induced at the 2-week study. Thus 7 of 28 
patients (25 % ) who did not have a favorable response 
after 1 week of amiodarone therapy had one after 2 
weeks of therapy. As noted previously, all electro- 
physiologic variables measured increased signifi- 
cantly from the baseline electrophysiology test to 
that performed after 1 week of loading with amio- 
darone. For some variables there was a continued ef- 
fect of amiodarone in group B when results of 1 and 
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Table III. Comparison of electrophysiologic effects of amiodarone within group B 
Effects Baseline 1 week Change 4 weeks Change 
Fastest VT CL 




Paced 600 msec 
HV interval 
SR 
Paced 600 msec 
QT interval 
SR 
Paced 600 msec 
QRS duration 
Paced 600 msec 
Paced 350 msec 
VERP 
600 msec DCL 
400 msec DCL 
VFRP 
600 msec DCL 
400 msec DCL 
257 + 47 
261 + 42 
835 2 96 
320 + 42 
374 t 94 
957 t 143 
63 + 50 
113 i 110 
123 i- 136 
365 -+ 55 
398 + 55 
983 i 151 
45 * 3!3* 
‘4 t 92 
26 f 91 
93 t 18 
122 * 34 
117 + 26 
203 i 67 
24 + 17 
80 -t 63 
123 * 31 
214 -’ 71 
ti 2 2’2 
11 T!Z 63 
49 * 7 
49 Lk I 
56 -t 9 
59 + 10 
7+7 
10 + 8 
60 + 10 
62 i 11 
4 i 12” 
:3 k 7 
388 + 37 
368 + 28 
474 t 55 
451 k 52 
81 _t 58 
83 + 54 
497 + 60 
469 ?I 52 
23 zk 53 
18 * 45 
196 i- 29 
212 i 46 
31 + 21 
44 +- 35 
209 + 31 
236 k 41 
13 i 20’ 
24 i 28” 
165 + 25 
168 k 26 
257 + 22 
237 r 21 
297 f 20 
279 * 33 
40 i 30 
43 + 41 
297 t 24 
274 + 20 
0 
5 i 36 
280 +- 21 
260 ir 18 
324 + 23 
295 f 19 
43 i: 29 
35 * 23 
325 + 25 
298 + 22 
1 t 17 
3 ? 19 
CL, Cycle length; DCL, drive cycle length; SR, sinus rhythm; VERP, ventricular effective refractory period; VFRP, ventricular functional refractory period. 
p < 0.05 or all comparisons baseline versus 1 week 
*p < 0.05 1 week versus 2 weeks. 
2 weeks of high-dose loading were compared. The 
cycle length of the fastest VT induced increased from 
320 -t 42 msec after 1 week of high-dose amiodarone 
loading to 365 + 55 msec after 2 weeks of high-dose 
loading (p < 0.05). The HV interval during sinus 
rhythm increased from 56 +- 9 msec at 1 week to 
60 + 10 msec after 2 weeks (p < 0.05). There was also 
a continued effect on ventricular conduction seen af- 
ter 2 weeks of high-dose loading. During ventricular 
pacing at a cycle length of 600 msec, the QRS dura- 
tion increased from 196 t 29 msec after 1 week to 
209 f 31 msec after 2 weeks (p < 0.05). A significant 
continued effect was also seen during ventricular 
pacing at a cycle length of 350 msec. 
Only eight subjects had a tachycardia of similar 
morphoogy induced at baseline and at the l- and 
2-week electrophysiologic tests. No significant in- 
crease in tachycardia cycle length was seen in this 
small group. However, six of eight patients did dem- 
onstrate a progressive increase in cycle length of in- 
duced VT. Values for individual patients are shown 
in Fig. 2. In addition, no significant change was seen 
between the l- and 2-week studies in the following 
electrophysiologic parameters: sinus cycle length, 
AH interval, HV interval during atria1 pacing, QT 
interval, or ventricular effective or functional refrac- 
tory periods. 
Plasma amiodarone concentrations. The plasma ami- 
odarone concentration was significantly higher 
(2.5 -t 1.1 yglml) after 1 week of oral loading with 
2400 mgjday of amiodarone than after 2 weeks of 
loading with a daily dose of 1200 mglday (1.6 -t 0.6 
pg/ml) (p = 0.0001). Although amiodarone concen- 
trations continued to rise after 2 weeks of high-dose 
loading (to 2.7 F 1.5 pg/ml), the change was not sig- 
nificant when compared to the l-week levels. Serum 
des-ethylamiodarone levels measured after 1 week of 
high-dose loading (0.89 & 0.36 pg/ml) were not sig- 
nificantly different from levels after 2 weeks in group 
A (0.85 2 0.26 pg/ml). In contrast to amiodarone, 
des-ethylamiodarone levels within group B were sig- 
nificantly higher after 2 weeks of high-dose loading 
(1.25 f 0.36 pg/ml) than after 1 week. 
Adverse effects within group B. During the first week 
of high-dose loading, the following adverse effects 
were seen: nausea (4 of 46), nausea and tremor (1 of 
46), nausea and lethargy (1 of 46), tremor alone (1 of 
46), dizziness (1 of 46), and congestive heart failure 
(1 of 46). One of the patients with nausea required 
dose reduction. During the second week of high-dose 
loading, 1 of 28 patients who had tremor required 
dose reduction and 1 of 28 who had tremor and nau- 
sea required dose reduction. One patient who re- 
ceived 2400 mglday of amiodarone for 14 days had 
adult respiratory distress syndrome 18 days after be- 
ginning amiodarone therapy. Results of a transbron- 
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chial biopsy showed only infiltration of inflammatory 
cells, and the syndrome resolved over 2 weeks. How- 
ever, for the purposes of this study the patient is 
considered to have had amiodarone pulmonary tox- 
icity. Thus although the incidence of side effects with 
a regimen of 2400 mg/day was 22 0;)) only one was se- 
rious and only one required a reduction in dosage 
during the loading phase. 
DISCUSSION 
Major findings. The major finding of this study is 
that suppression of inducible VT by amiodarone can 
be achiec-ed in a similar proportion of patients if a 
loading dose of 16.8 gm is given over either 7 or 14 
days. In addition, both loading regimens produced 
similar changes in the electrophysiologic parameters 
measured in this study. A daily dose of 2400 mg/day 
of amiodarone was well tolerated in the majority of 
patients. This rapid high-dose loading regimen has 
the potential for shortening the period of hospital- 
ization during t,he initiation of amiodarone therapy 
for VT. 
Regimens for oral amiodarone loading. Single-dose 
pharmacokinetic data have shown amiodarone to 
have a very large volume of distribution and a long 
terminal elimination half-life.12 These prolong the 
time necessary to reach steady-state tissue levels of 
the drug and result in a time lag between initiation 
of therapy and antiarrhythmic effect if therapy is 
initiated with maintenance doses of amiodarone. By 
use of noninvasive means to determine arrhythmia 
suppression, Rakita and Soboll showed that large 
initial doses of amiodarone were well tolerated and 
shortened t.he time needed to achieve arrhythmia 
control. 
Up to 10 weeks of therapy with oral amiodarone is 
required to produce the electrophysiologic effects 
seen chronically. Kadish et a1.g demonstrated that 
when the electrophysiologic effects of amiodarone 
Jere compared between 2 weeks and 3 months of 
therapy, a progressive increase in the cycle length of 
induced VT and in the vent.ricular effective refrac- 
tory period were noted. Other investigators have 
demonstrated similar results.3 To determine the time 
course of the onset of the electrophysiologic and an- 
tiarrhythmic effects of amiodarone more precisely, 
Mitchell et aLi3 performed serial electrophysiologic 
testing beginning 2 weeks after the initiation of a 
standardized oral loading regimen of amiodarone. 
The maximum effect on VT inducibility and cycle 
length was not seen until 10 weeks after initiation of 
t,herapy, well beyond the initial 2 weeks of high-dose 
loading. 
It is not practical to hospitalize patients for 10 
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Fig. 2. Cycle length of (CL) of induced ventricular tachy- 
cardia (VT) in eight patients in group B who had VT of 
similar morphology induced during all three electrophysi- 
ologic tests. In six of eight patients, cycle length of induced 
VT increased progressively from baseline to l-week to 
2-week study. In one patient, cycle length of induced VT 
decreased from baseline to l-week study and then in- 
creased from the l-week to 2-week study and then in- 
creased from baseline to l-week study and then decreased 
from l-week to 2-week study. This patient also had second 
faster VT morphology induced and thus continued for sec- 
ond week of high-dose amiodarone. 
weeks, and therefore in patients with life-threatening 
arrhythmias, “early” electrophysiologic testing has 
been utilized to determine whether it is safe to dis- 
charge patients on a regimen of oral amiodar0ne.l.” A 
two-week loading period with oral amiodarone at a 
dosage of 600 to 1800 mg/day has been used in most 
previous studies before electrophysiologic test- 
ing.ls, 14-lg Although Rosenfeld et aL20 performed 
electrophysiologic testing in 25 patients after 1 week 
of 1200 mglday of amiodarone, a comparison with a 
2-week loading regimen was not performed. A pre- 
liminary report published in 1984 compared l- and 
Z-week amiodarone loading regimens; however, that 
study has not yet appeared in expanded form.21 The 
total daily dose of amiodarone was limited to 1800 
mg/day in the studies noted previously. However, 
Mostow et a1.22 used up to 4.4 gm/day to achieve rapid 
suppression of ventricular arrhythmias. Only 1 of 18 
patients had serious side effects. 
Electrophysiologic effects of the high-dose regimen. 
In the present study, 1 week of amiodarone therapy 
at a dosage of 2400 mg/day produced significant in- 
creases in sinus cycle length, atrioventricular and 
ventricular conduction intervals, cycle length of 
induced VT, and ventricular refractory periods. 
372 Summitt, Morady, and Kadish 
These effects were similar to the effects of conven- 
tional loading regimens both in this and other 
studies.3T g, 13* 23-27 In the 28 patients who received a 
second week of 2400 mglday of amiodarone, indexes 
of His-Purkinje and ventricular conduction (HV in- 
terval, QRS duration, and cycle length of induced 
VT) showed a progressive increase, whereas indexes 
of ventricular repolarization (ventricular effective 
refractory period, ventricular functional refractory 
period, and QT interval) did not. 
Efficacy and toxicity of the high-dose regimen. Most 
prior studies have demonstrated that amiodarone 
only infrequently suppresses the induction of sus- 
tained VT at electropharmacologic testing.leg, 15, I6 
For example, Horowitz et a1.l demonstrated that if 
100 patients with inducible sustained VT at baseline 
electrophysiologic testing had coronary artery dis- 
ease, only 20 (20%) had the induction of sustained 
VT suppressed at electropharmacologic testing. Sup- 
pression of the induction of sustained VT was 
achieved in a similar percentage of patients in the 
present study (13 YC with the standard-dose regimen 
and 22% with the high-dose regimen). In addition, 
amiodarone rendered the induced VT hemodynam- 
ically stable in several additional patients as demon- 
strated in prior studies.ll 2 
Although minor side effects were relatively fre- 
quent during the high-dose loading regimen, only one 
patient required a reduction in dosage during the 
loading phase. In addition, 4 days after the comple- 
tion of 2 weeks of high-dose amiodarone therapy, one 
patient had apparent pulmonary toxicity. “Early” 
pulmonary toxicity has also been seen with a stan- 
dard loading regimen. 28 Three of 89 patients in one 
prior study had pulmonary toxicity during the first 
month of amiodarone therapy with a loading regimen 
that was generally 1400 mgjday for 2 weeks.28 Thus 
our case of pulmonary toxicity does not appear to be 
unique to the high-dose loading regimen. 
Limitations. The data presented concern only the 
acute loading phase of amiodarone therapy. No 
attempt was made to correlate results of electro- 
pharmacologic testing with long-term clinical out- 
come. Although the predictive value of electrophys- 
iologic testing after 1 week of high-dose therapy has 
been presumed to be as good as after 2 weeks of ther- 
apy, this remains to be established. In addition, only 
two dosing regimens were compared in the present 
study. No conclusions regarding other potential load- 
ing regimens can be drawn from the present results. 
Clinical implications. The need for amiodarone has 
been found to be a major determinant of the length 
of hospital stay and the cost in patients undergoing 
electrophysiologic testing because of the long period 
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of time required for loading.27 Our findings suggest 
that a loading phase of 2400 mglday of amiodarone 
for 1 week may be clinically useful. This should result, 
in ‘a shortened hospitalization and substantial cost 
savings. Most patients who persist in having induc- 
ible hemodynamically unstable VT after 1 week of 
amiodarone therapy should receive alternative ther- 
apy, because the response rate to a second week of 
high-dose therapy is small. However, occasional pa- 
tients who are poor candidates for other forms of 
therapy may benefit from treatment with an addi- 
tional week of amiodarone. 
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